EDAP’s Focal One Revenue Is Set To Accelerate
The placement of new Focal Ones got off to a good start this year and a filled-up pipeline is promising more, boosted by a big reimbursement improvement for Medicare. Reimbursement […]
Acceleration At EDAP
After a somewhat disappointing Q3 and a disappointing reimbursement decision, things definitely picked up in Q4. We see a bright future ahead with a large market to go after, installations […]
EDAP’s HIFU Progress Is Obscured By The Pandemic, But It’s Real
Favorable changes in market acceptance and reimbursement for the FocalOne have been obscured by pandemic headwinds. However, the company continues at breakeven because of strong growth in its distribution business, […]
EDAP TMS: A Little Medical Growth Gem
The company is already growing sequentially, even if 2020 revenues were down on those in 2019. Still small in relation to a large and growing TAM, and working on an […]
EDAP Set For Long-Term Growth
The company offers an innovative device that produces non-invasive HIFA treatment for prostate cancer with other applications to follow. Despite the pandemic and reimbursement which is yet to be settled, […]
EDAP Shares Are Still A Steal, But The Pandemic Could Be A Wrench
EDAP has developed an innovative HIFU treatment device for prostate and other cancers, which it was already selling. The offering is boosted by an exclusive distribution deal with the maker […]
(Exclusive) The Selloff In EDAP Looks Overdone
EDAP, developer of promising medical devices for HIFU and ESWL treatments, has been buffeted by hospitals concentrating on treating Covid-19 patients. However, this looks like postponement to us, with little […]
EDAP Is At An Inflection Point
The company is in the first inning with its HIFU treatment of prostate cancer, enjoying near triple-rate growth in Q2. Its other business is more steady, but also had a […]